Prostate Cancer Patient Anxiety Independently Predicts Early Start Of Androgen Deprivation Therapy For Biochemical Cancer Recurrence In Older Men
Editor's ChoiceMain Category: Prostate / Prostate Cancer
Also Included In: Urology / Nephrology; Cancer / Oncology
Article Date: 31 Mar 2009 - 4:00 PDT
UroToday.com - Dr. William Dale and associates reported on the influence of anxiety when a patient with prostate cancer (CaP) and biochemical recurrence (BCR) initiates androgen deprivation therapy (ADT).
A total of 67 patients with a mean age of 68 years participated and 70% of these rated their own health as very good or excellent. Data was collected from surveys and medical records. Participants completed an initial baseline survey and a follow-up at each subsequent visit until they started ADT. Metrics assessed through numerous validated instruments included demographics, psychological state and physical functioning. The patient's perception of his and the physician's relative contributions to the decision to initiate ADT were asked. The relative importance of 16 factors related to the initiation of ADT were ranked from 1 (not important) to 5 (very important).
The anxiety evaluation demonstrated excellent internal consistency reliability. Elevated CaP-specific anxiety was present in 22% at presentation. Both attending oncologists and oncology fellows rated PSA doubling time as the most important factor in deciding when to start a patient with BCR on ADT. They rated patient anxiety as the third least important factor, but patient preference as the second most important factor. Several multivariable models were assessed. Elevated anxiety was the strongest predictor of early ADT and correctly classified 74% of the cases. PSA also independently correlated with early initiation of ADT, but PSA did not correlate with anxiety scores. However, in 2 of the multivariable models, PSA doubling time was not even significant. In participants with elevated anxiety scores, the average time to initiation of ADT was 11 months after presentation. In men with lower anxiety it was 24.9 months.
The study is remarkable in documenting that patient anxiety is more important than clinical parameters in determining the time to initiation of ADT in men with a BCR of CaP.
Dale W, Hemmerich J, Bylow K, Mohile S, Mullaney M, Stadler WM
J Clin Oncol. 2009 Mar 2. (Epub ahead of print)
10.1200/JCO.2008.18.5850
Written by UroToday.com Contributing Editor Christopher P. Evans, MD, FACS
UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.
To access the latest urology news releases from UroToday, go to: www.urotoday.com
Copyright © 2009 - UroToday
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today
MLA
12 Feb. 2012. <http://www.medicalnewstoday.com/articles/144350.php>
APA
http://www.medicalnewstoday.com/articles/144350.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Visitor Opinions In Chronological Order (1)
Not Surprising To Me
posted by John Thomas on 2 Apr 2009 at 4:01 amI am not in the slightest surprised that PATIENTS would be more influenced by anxiety than medical test parameters.
As a man, age 57, general health excellent, with a long history (10+ years) of generalized anxiety disorder and recent high PSA 5.9 but negative PCa biopsy, I am still worried. And in the situation described, that is, men with recurrent cancer, it doesn't surprise me in the slightest that emotion prevails over medical logic in the patient's decision to undergo or not undergo treatment.
I am glad the study was conducted, so that PHYSICIANS will understand this, but it's all-too-obvious to me, and I suspect, most men who suffer from even mild anxiety.
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




